Pfizer Reports the First Patients Dosing of PF-06939926 in P-III CIFFREO Study for DMD
Shots:
- The first patient has been dosed in P-III CIFFREO study assessing PF-06939926 vs PBO in 99 ambulatory male patients aged 4-7yrs. with DMD across 55 sites in 15 countries.
- The first patient was dosed at a site in Barcelona- Spain on Dec 29- 2020. The 1EPs of the study is the change in NSAA @1yr- while patients will be followed in the CIFFREO study for 5yrs. after treatment with PF-06939926
- PF-06939926 is an investigational rAAV9 capsid carrying a shortened version of the human dystrophin gene (mini-dystrophin) under the control of a human muscle-specific promotor and has received the US FDA’s FT designation in Oct’2020 and ODD & RPD in May’2017
Ref: Businesswire | Image: Wall Street Journal
Click here to read the full press release
This content piece was prepared by our former Senior Editor. She had expertise in life science research and was an avid reader. For any query reach out to us at connect@pharmashots.com